---
id: brain-abscess_087
category: clinical_syndromes
tags: [brain-abscess, intracranial-abscess, metronidazole, neurosurgery, drainage]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Brain Abscess

**Q:** What are the risk factors, microbiology, diagnostic approach, and management (medical + surgical) of brain abscesses?

**A:**

**Definition:**
- **Brain Abscess:** Focal suppurative infection within brain parenchyma
- **Subdural Empyema:** Pus collection between dura and arachnoid
- **Epidural Abscess:** Pus collection between skull and dura

---

## EPIDEMIOLOGY

**Incidence:**
- **0.4-0.9 cases per 100,000** annually
- **More common in developing countries**

**Mortality:**
- **10-15%** (with treatment; 30-40% before antibiotics)
- **Neurologic sequelae:** 30-50% (seizures, focal deficits)

---

## PATHOGENESIS

**Routes of Infection:**

### **1. Contiguous Spread (40-50% of Cases)**

**Sources:**
- **Sinusitis** (especially sphenoid, frontal) → Frontal lobe abscess
- **Otitis media, mastoiditis** → Temporal lobe, cerebellar abscess
- **Dental infection** → Frontal lobe abscess

**Organisms:**
- **Polymicrobial** (oral flora)
  - **Streptococcus** (*S. anginosus* group - #1 for brain abscess)
  - **Anaerobes:** *Bacteroides*, *Prevotella*, *Fusobacterium*, **Anaerobic cocci** (*Peptostreptococcus*, *Finegoldia magna*)

**Key Point:** **Sinusitis/otitis → brain abscess** (most common route)

---

### **2. Hematogenous Spread (25-35%)**

**Sources:**
- **Endocarditis** (especially right-to-left shunt)
- **Chronic lung infections:** Lung abscess, empyema, bronchiectasis
- **Bacteremia** (any source)
- **Congenital heart disease** (cyanotic - Tetralogy of Fallot, TGA)

**Organisms:**
- ***Staphylococcus aureus*** (MSSA, MRSA)
- ***Streptococcus* species**
- **Gram-negative bacilli** (*E. coli*, *Klebsiella*)

**Key Finding:**
- **Multiple abscesses** (suggests hematogenous spread)

**Key Point:** **Multiple abscesses = hematogenous spread** (search for endocarditis, lung infection)

---

### **3. Direct Inoculation (10-15%)**

**Sources:**
- **Penetrating head trauma** (gunshot wound, open skull fracture)
- **Neurosurgery** (craniotomy, shunt)

**Organisms:**
- ***Staphylococcus aureus*** (MSSA, MRSA)
- **Coagulase-negative Staphylococci (CoNS)** (*S. epidermidis*)
- **Gram-negative bacilli** (*Pseudomonas*, *Acinetobacter*)
- ***Cutibacterium acnes*** (formerly *Propionibacterium acnes*)

---

### **4. Cryptogenic (15-30%)**

**No identifiable source**

---

## MICROBIOLOGY

**Most Common Organisms:**

| **Source** | **Organisms** |
|------------|---------------|
| **Contiguous (sinusitis, otitis, dental)** | ***S. anginosus* group** (#1)<br>**Anaerobes** (*Bacteroides*, *Prevotella*, *Fusobacterium*, anaerobic cocci)<br>Viridans streptococci |
| **Hematogenous** | ***S. aureus***<br>Streptococci<br>Gram-negative bacilli |
| **Post-neurosurgery/trauma** | ***S. aureus*** (MRSA)<br>**CoNS**<br>*Pseudomonas*, *Acinetobacter*<br>*Cutibacterium acnes* |
| **Immunocompromised** | ***Toxoplasma gondii*** (HIV, CD4 <100)<br>*Nocardia asteroides*<br>*Aspergillus*, *Candida*<br>*Mycobacterium tuberculosis* |

**Key Point:** ***Streptococcus anginosus* group = #1 organism** for brain abscess (40-50% of cases)

---

## CLINICAL PRESENTATION

**Classic Triad (Only 20% Have All Three):**
- **Fever** (50%)
- **Headache** (70%)
- **Focal neurologic deficit** (50%)

**Other Features:**
- **Seizures** (25-50%)
- **Altered mental status** (30%)
- **Nausea/vomiting** (40%)
- **Papilledema** (25% - ↑ ICP)
- **Neck stiffness** (15% - less common than meningitis)

**Key Point:** **Brain abscess = headache + focal deficit** (fever may be ABSENT in 50%)

---

**Time Course:**
- **Subacute onset** (days to weeks) - slower than meningitis/encephalitis
- **Early cerebritis** (days 1-3): Poorly defined inflammation
- **Late cerebritis** (days 4-9): Central necrosis
- **Capsule formation** (days 10-14): Well-defined ring-enhancing lesion

---

## DIAGNOSIS

---

### **Step 1: Neuroimaging (MRI > CT)**

**MRI Brain With Contrast (GOLD STANDARD):**

**Classic Finding:**
- **Ring-enhancing lesion** with surrounding edema
- **Smooth, thin, well-defined capsule**
- **Central hypodensity** (pus)

**MRI Sequences:**
- **T1 + Gadolinium:** Ring enhancement
- **T2/FLAIR:** Surrounding vasogenic edema (bright)
- **Diffusion-Weighted Imaging (DWI):** **Restricted diffusion** (bright on DWI, dark on ADC)
  - **Key Point:** **Restricted diffusion (DWI-bright) = abscess** (NOT tumor, which is NOT restricted)

---

**CT Head With Contrast (If MRI Unavailable):**
- **Ring-enhancing lesion**
- **Surrounding hypodensity** (edema)
- **MRI more sensitive** (detects early cerebritis before capsule formation)

---

**Location:**
- **Frontal lobe** (sinusitis, dental)
- **Temporal lobe, cerebellum** (otitis media, mastoiditis)
- **Multiple locations** (hematogenous)

---

### **Step 2: Blood Cultures**

**Always obtain ≥2 sets:**
- **Positive in 10-20%** (higher if hematogenous source)

---

### **Step 3: Lumbar Puncture (LP) - USUALLY CONTRAINDICATED**

**LP is CONTRAINDICATED if:**
- **Mass lesion on CT/MRI** (risk of herniation)
- **↑ Intracranial pressure** (papilledema)

**If LP Performed (Rare):**
- **CSF:** Nonspecific (WBC 10-500, protein elevated, glucose normal)
- **Culture:** Low yield (<10% positive)
- **Risk of herniation** >> Benefit

**Key Point:** **Do NOT perform LP if brain abscess suspected** (risk of herniation)

---

### **Step 4: Stereotactic Aspiration / Surgical Drainage (Diagnostic + Therapeutic)**

**Indications:**
- **All brain abscesses** (unless too small <2 cm or multiple)
- **Send for:**
  - **Gram stain, culture** (aerobic + anaerobic)
  - **Fungal stain, culture**
  - **AFB stain, TB culture**
  - **Pathology** (rule out tumor, malignancy)

**Yield:**
- **Culture positive:** 70-90%

---

## MANAGEMENT

**Key Principle:** **Antibiotics + Surgical Drainage** (medical therapy alone usually insufficient)

---

### **Step 1: Empiric Antibiotic Therapy (BEFORE Culture Results)**

**Start antibiotics immediately:**
- **Do NOT delay for surgery**
- **Cover most likely organisms** based on source

---

**Empiric Regimen by Source:**

---

#### **A. Contiguous Spread (Sinusitis, Otitis, Dental):**

**Coverage:** Streptococci + Anaerobes

| **Agent** | **Dosing** |
|-----------|------------|
| **Ceftriaxone** OR **Cefotaxime** | 2g IV q12h OR 2g IV q4-6h |
| **PLUS** | |
| **Metronidazole** | 500 mg IV q8h |
| **PLUS (Consider)** | |
| **Vancomycin** | 15-20 mg/kg IV q8-12h (if concern for MRSA) |

**Rationale:**
- **Ceftriaxone:** Streptococci (*S. anginosus*, viridans strep)
- **Metronidazole:** Anaerobes (*Bacteroides*, *Prevotella*, *Fusobacterium*, anaerobic cocci)
- **Vancomycin:** If MRSA concern (recent hospitalization, IVDU)

---

#### **B. Hematogenous (Endocarditis, Lung, Unknown):**

**Coverage:** *S. aureus* + Streptococci + Gram-negatives

| **Agent** | **Dosing** |
|-----------|------------|
| **Vancomycin** | 15-20 mg/kg IV q8-12h |
| **PLUS** | |
| **Ceftriaxone** OR **Cefotaxime** | 2g IV q12h OR 2g IV q4-6h |
| **PLUS** | |
| **Metronidazole** | 500 mg IV q8h |

**Alternative (If Gram-negatives Likely):**
- **Cefepime** 2g IV q8h OR **Meropenem** 2g IV q8h (instead of ceftriaxone)

---

#### **C. Post-Neurosurgery / Trauma:**

**Coverage:** MRSA + CoNS + *Pseudomonas*

| **Agent** | **Dosing** |
|-----------|------------|
| **Vancomycin** | 15-20 mg/kg IV q8-12h |
| **PLUS** | |
| **Cefepime** OR **Ceftazidime** OR **Meropenem** | 2g IV q8h |

---

#### **D. Immunocompromised (HIV, Transplant):**

**Coverage:** *Toxoplasma* + *Nocardia* + Fungi + Bacteria

| **Agent** | **Dosing** |
|-----------|------------|
| **Pyrimethamine** + **Sulfadiazine** + **Leucovorin** | 200 mg PO x1, then 50-75 mg PO daily<br>1-1.5g PO QID<br>10-20 mg PO daily |
| **OR TMP-SMX** | 5 mg/kg (TMP) IV q6h |
| **PLUS (If concern for bacteria)** | |
| **Vancomycin + Ceftriaxone + Metronidazole** | As above |

**If *Toxoplasma* likely (HIV, CD4 <100):**
- **Start empiric toxoplasmosis treatment**
- **If no improvement in 7-14 days → Biopsy** (to rule out CNS lymphoma)

---

### **Step 2: Targeted Therapy (After Culture Results)**

| **Organism** | **Regimen** | **Duration** |
|--------------|-------------|--------------|
| **Streptococci** (*S. anginosus*, viridans) | **Penicillin G** 24 million units/day IV OR **Ceftriaxone** 2g IV q12h | **4-6 weeks** |
| ***S. aureus*** (MSSA) | **Nafcillin** OR **Oxacillin** 2g IV q4h | **4-6 weeks** |
| ***S. aureus*** (MRSA) | **Vancomycin** 15-20 mg/kg IV q8-12h | **4-6 weeks** |
| **Anaerobes** (*Bacteroides*, etc.) | **Metronidazole** 500 mg IV q8h | **4-6 weeks** |
| ***Nocardia asteroides*** | **TMP-SMX** 5 mg/kg (TMP) IV q6h | **≥12 months** |
| ***Toxoplasma gondii*** | **Pyrimethamine + Sulfadiazine + Leucovorin** | **≥6 weeks**, then maintenance |
| **Fungi** (*Aspergillus*, *Candida*) | **Voriconazole** OR **Amphotericin B** + Surgery | **≥6-12 weeks** |

---

### **Step 3: Surgical Management**

---

**Indications for Drainage:**

**Stereotactic Aspiration (Preferred):**
- **Abscess ≥2.5 cm**
- **Accessible location**
- **Diagnostic + Therapeutic**

**Open Surgical Excision:**
- **Multiloculated abscess** (aspiration fails)
- **Fungal abscess** (thick-walled)
- **Traumatic abscess** (foreign material)

---

**Contraindications to Surgery:**
- **Multiple small abscesses** (<2 cm) - medical therapy only
- **Early cerebritis** (before capsule formation) - antibiotics alone
- **Surgically inaccessible location** (brainstem, thalamus)

---

**Serial Imaging:**
- **Repeat MRI every 1-2 weeks** (monitor abscess size)
- **Consider repeat aspiration** if enlarging despite antibiotics

---

### **Step 4: Adjunctive Therapy**

---

**A. Corticosteroids (CONTROVERSIAL):**

**Indications:**
- **Severe cerebral edema** with ↑ ICP
- **Mass effect** with impending herniation

**Dosing:**
- **Dexamethasone** 10 mg IV, then 4 mg IV q6h

**Key Point:** **Avoid corticosteroids if possible** (may impair antibiotic penetration, delay capsule formation)

---

**B. Antiepileptics (For Seizure Prophylaxis):**

**Indications:**
- **Seizure at presentation** (treat)
- **Prophylaxis:** Controversial (some recommend levetiracetam or phenytoin x 3-6 months)

**Regimen:**
- **Levetiracetam** 500-1000 mg PO BID
- **OR Phenytoin** (loading dose 15-20 mg/kg, then 100 mg TID)

---

## DURATION OF THERAPY

**Antibiotic Duration:**
- **Bacterial abscess:** **4-6 weeks IV** (at least 4 weeks after drainage)
- **Fungal abscess:** **≥6-12 weeks**
- ***Nocardia*:** **≥12 months** (high relapse rate)
- ***Toxoplasma*:** **≥6 weeks acute**, then **lifelong suppression** (if HIV)

**Transition to Oral:**
- **Consider after 2-4 weeks IV** (if clinical improvement + abscess resolving on imaging)
- **High-dose oral regimens** (e.g., amoxicillin 1g PO TID, metronidazole 500 mg PO TID)

---

## MONITORING

**Serial MRI:**
- **Every 1-2 weeks** initially
- **Monitor abscess size** (should decrease by 50% within 4 weeks)

**Repeat Aspiration/Surgery If:**
- **Abscess enlarging** despite antibiotics
- **No clinical improvement** after 2 weeks

---

## COMPLICATIONS

**1. Rupture Into Ventricle:**
- **Ventriculitis** (high mortality 50-80%)
- **Emergency ventriculostomy + antibiotics**

**2. Herniation:**
- **Uncal herniation** (transtentorial)
- **Emergency neurosurgical decompression**

**3. Seizures:**
- **25-50% develop seizures** (acute or chronic)

**4. Neurologic Sequelae:**
- **30-50%** (motor deficits, cognitive impairment, epilepsy)

---

## PROGNOSIS

**Mortality:**
- **10-15%** (with treatment)
- **Higher mortality:** Intraventricular rupture (50-80%), fungal abscess (30-50%)

**Predictors of Poor Outcome:**
- **Altered mental status** at presentation (GCS <8)
- **Rupture into ventricle**
- **Multiple abscesses**
- **Fungal etiology**
- **Delayed treatment**

---

**Mnemonic: "SCAM for Brain Abscess Sources"**
- **S**inusitis (frontal lobe)
- **C**ardiac (endocarditis, congenital heart disease - multiple abscesses)
- **A**ural (otitis media, mastoiditis - temporal lobe, cerebellar)
- **M**outh (dental - frontal lobe)

**Mnemonic: "Strep Anginosus = Abscess Anywhere"**
- ***S**treptococcus **A**nginosus* group
- **A**bscess formation (brain, liver, lung)

**Mnemonic: "DWI-Bright = Abscess (Not Tumor)"**
- **D**WI (diffusion-weighted imaging)
- **B**right on DWI = **Restricted diffusion**
- **A**bscess (vs tumor - NOT restricted)

**Clinical Pearls:**
- **Brain abscess = headache + focal deficit** (fever may be ABSENT in 50%)
- ***S. anginosus* group = #1 organism** (40-50% of cases)
- **Contiguous spread (sinusitis, otitis) = most common route** (40-50%)
- **Multiple abscesses = hematogenous spread** (search for endocarditis, lung infection)
- **MRI > CT** (detects early cerebritis, DWI shows restricted diffusion)
- **DWI-bright (restricted diffusion) = abscess** (NOT tumor)
- **DO NOT perform LP** if brain abscess suspected (risk of herniation)
- **Empiric therapy:** Ceftriaxone + metronidazole (contiguous) OR Vancomycin + ceftriaxone + metronidazole (hematogenous)
- **Surgical drainage essential** (aspiration or excision) - medical therapy alone insufficient
- **Antibiotics x 4-6 weeks** (at least 4 weeks after drainage)
- **Avoid corticosteroids if possible** (impair antibiotic penetration, delay capsule formation)
- **Seizure risk 25-50%** (consider prophylaxis)
- **Neurologic sequelae 30-50%** (motor, cognitive, epilepsy)
- **Toxoplasma in HIV (CD4 <100):** Empiric treatment x 7-14 days → Biopsy if no improvement (rule out CNS lymphoma)
- ***Nocardia* abscess:** TMP-SMX x ≥12 months (high relapse rate)

**Media:** None

**Sources:** [Lancet 2024 - Brain abscess], [IDSA 2017 - Brain abscess management], [Neurosurgery 2023 - Stereotactic aspiration vs excision], [NEJM 2022 - CNS infections], [Clinical Infectious Diseases 2024 - Microbiology of brain abscess]
